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Prostaglandin E2 stimulates normal
bronchial epithelial cell growth through
induction of c-Jun and PDK1, a kinase
implicated in oncogenesis
Yu Fan1,2, Ye Wang1 and Ke Wang1*
Abstract
Background: Cyclooxygenase-2-derived prostaglandin E2 (PGE2), a bioactive eicosanoid, has been implicated in
many biological processes including reproduction, inflammation and tumor growth. We previously showed that
PGE2 stimulated lung cancer cell growth and progression through PGE2 receptor EP2/EP4-mediated kinase signaling
pathways. However, the role of PGE2 in controlling lung airway epithelial cell phenotype remains unknown. We
evaluated the effects of c-Jun and 3-phosphoinositede dependent protein kinase-1 (PDK1) in mediating epithelial
cell hyperplasia induced by PGE2.
Method: The bronchial epithelial cell lines BEAS-2B and HBEc14-KT were cultured and then treated with PGE2. PDK1
small interfering RNA (siRNA) and a PDK1 inhibitor, an antagonist of the PGE2 receptor subtype EP4 and EP4 siRNA,
c-Jun siRNA, and overexpressions of c-Jun and PDK1 have been used to evaluate the effects on cell proliferation.
Results: We demonstrated that PGE2 increased normal bronchial epithelial cell proliferation through induction of
PDK1, an ankyrin repeat-containing Ser/Thr kinase implicated in the induction of apoptosis and the suppression
of tumor growth. PDK1 siRNA and a PDK1 inhibitor blocked the effects of PGE2 on normal cell growth. The PGE2-
induced PDK1 expression was blocked by an antagonist of the PGE2 receptor subtype EP4 and by EP4 siRNA. In
addition, we showed that induction of PDK1 by PGE2 was associated with induction of the transcription factor,
c-Jun protein. Silencing of c-Jun using siRNA and point mutations of c-Jun sites in the PDK1 gene promoter
resulted in blockade of PDK1 expression and promoter activity induced by PGE2. In contrast, overexpression of
c-Jun induced PDK1 gene promoter activity and expression followed increased cell proliferation.
Conclusion: PGE2 increases normal bronchial epithelial cell proliferation through increased PDK1 gene expression
that is dependent on EP4 and induction of c-Jun. Therewith, our data suggest a new role of c-Jun and PDK1 in
mediating epithelial cell hyperplasia induced by PGE2.
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Background
Cancer claims over half a million lives in the United
States annually, and lung cancer is the number one
cause of cancer death in both men and women. An esti-
mated 226,160 new cases of lung cancer was diagnosed
in 2012 in the United States alone, and 160,340 lung
cancer deaths are estimated to occur [1]. Chronic in-
flammation has been associated with an increased risk of
cancer. Protein levels of cyclooxygenase-2 (COX-2), a
mediator of inflammation, were reported elevated in sev-
eral cancer types, including colorectal, prostate, and lung
cancers, and suppression of either COX-2 expression or
COX-2 activation, is being considered for cancer preven-
tion and therapy [2]. Of the five prostaglandins (PG)
produced by COX-2, PGE2 appeared to play essential
roles in tumor cell proliferation, invasion, angiogenesis,
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and immunosuppression [3–5]. Four receptor subtypes
are known to bind PGE2, and they are named EP1-4.
These receptors have also been implicated in tumor cell
growth and progression [6, 7]. PGE2 is increased in pa-
tients with chronic obstructive pulmonary disease also
showing a higher incidence of lung cancer [8].
Three-phosphoinositede dependent protein kinase-1
(PDK1) is a master kinase, which is crucial for the activa-
tion of AKT / protein kinase B (PKB) and many other
AGC kinases including protein kinase C (PKC), S6 protein
kinase (S6K), and serum-and glucocorticoid-induced pro-
tein kinase (SGK) [9]. As an upstream regulator of AKT,
PDK1 signaling is thought to play a key role in cancer cell
growth, survival and tumor angiogenesis [10, 11]. Studies
have shown high levels of activated PDK1 in a large per-
centage of common tumor types, including melanoma,
breast, lung, gastric, prostate, hematological, and ovarian
cancers [12]. When activated in tumor cells, Akt also has
multiple effects that promote disease progression, in-
cluding suppression of apoptosis and stimulation of tumor
cell proliferation, metabolism, and angiogenesis [13–15].
Thus, the PDK1/Akt signaling pathway represents an
attractive target for the development of small molecule in-
hibitors that may be useful in the treatment of cancer.
However, the effects of PGE2 on human bronchial epithe-
lial cells are not clear. Here, we explore the effects of
PGE2 on human bronchial epithelial cell proliferation and
the intracellular signals involved in this process. Our stud-
ies show that PGE2 stimulates human bronchial epithelial
cell proliferation through the EP4 receptor and activation
of c-Jun, which increases the expression of PDK1.
Methods
Cell culture and chemicals
The human bronchial epithelial cell lines BEAS-2B and
HBEc14-KT were obtained from John Minna (University
of Texas Southwestern Medical Center, Dallas, TX, USA).
They were maintained in KERATINOCYTE-SFM medium
(Invitrogen Corporation, Carlsbad, CA, USA) supplemen-
ted with human recombinant epidermal growth factor
1–53 (EGF 1–53) and bovine pituitary extract (BPE). Cells
were plated into six-well culture plates at an initial seeding
density of 5 × 104 cells per well. The plates were incubated
in a humidified atmosphere of 5 % CO2 in air at 37 °C.
Lipofectamine 2000 reagent was purchased from Invitro-
gen. The CellTiter-Glo Luminescent Cell Viability Assay
kit was purchased from Promega. Polyclonal antibodies
against PDK1 and phosphorylated PDK1 (ser 241) were
purchased from Cell Signaling. The polyclonal antibody
against c-Jun was purchased from Santa Cruz Bio-
technology, Inc. Polyclonal antibody against EP4, a 16,
16-Dimethyl-PGE2 (dmPGE2) solution in methyl acetate
and AH23848, OSU-03012 were purchased from Cayman
Chemical Co.
Reverse transcription and real time PCR
Real time PCR was performed to assess whether PDK1
expression was modulated by PGE2. Total RNA was iso-
lated using the RNA Bee kit (Qiagen, Inc., Valencia, CA)
as per manufacturer’s instructions. One μg of total RNA
was reverse transcribed as per protocol using TaqMan®
RT reagents (Applied Biosystems) at 37 °C for 120 min
followed by 25 °C for 10 min.
Forty ng of cDNA per reaction were used in the real
time PCR using the ABI Prism® 7900HT Sequence Detec-
tion System (Foster City, CA). In the presence of Ampli-
Taq Gold DNA polymerase (ABI Biosystems, Foster City,
CA), the reaction was incubated for 2 min at 50 °C
followed by 10 min at 95 °C. Then the reaction was run
for 40 cycles at 15 s, 95 °C and 1 min, 60 °C per cycle
(Table 1). Assays-on-Demand™ primers and probes spe-
cific for the oxytocin receptor (Applied Biosystems; ID
number Hs00168573-m1) were used in the PCR. GAPDH
was measured and used to normalize all samples using the
ΔΔCT method (Applied Biosystems). Gene expression of
PDK1 is expressed relative to GAPDH and untreated sam-
ples in each stimulation study, respectively. At least three
replicates were run for each condition.
Western blot analysis
The procedure was performed as previously described
[16]. Protein concentrations were determined by the Bio-
Rad protein assay. 5 μg protein from whole-cell lysates
were solubilized in 5× SDS sample buffer and separated
on SDS 10 % polyacrylamide gels. Blots were incubated
with antibodies against c-Jun, PDK1, EP4, GAPDH, and
phosphorylated PDK1 (c-Jun, PDK1, pPDK1 and EP4 in
the concentrations of 1:1,000 for 2 h; GAPDH in the con-
centration of 1:10000 for 1 h) at room temperature. After
washing several times, the blots were followed by incuba-
tion with a secondary goat antibody raised against rabbit
IgG conjugated to horseradish peroxidase (1:2,000; Santa
Cruz). The blots were washed, transferred to fresh chemi-
luminescence solution (Amersham) for about 1–2 min,
and exposed to X-ray film. In controls, the primary anti-
bodies were omitted or replaced with a control rabbit IgG.
Table 1 Reverse transcription and real time PCR primer
Stage Temp Time
Reverse transcription hold 37 °C 120 min
hold 25 °C 10 min
PCR hold 50 °C 2 min
denature 95 °C 15 s
anneal/extend 60 °C 1 min
hold cycle (40 cycles) 95 °C 10 min
Primer Sense 5′ AGATGAGTGACCGAGGAG
Antisense 3′ TATACACTGGGAGTCTTTCT
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Treatments with EP4, PDK1, and c-Jun small interfering
RNA and expression vector
The EP4, PDK1, c-Jun siRNA and control nonspecific
siRNA oligonucleotides were purchased from Santa Cruz
Biotechnology. pWZL-Neo-Myr- Flag PDK1 and pWZL-
Neo-Myr-Flag-DEST were purchased from Addgene Inc.
The pGME4 c-Jun vector and pGME4 were provided by
Dr. Tom Curran (Children’s Hospital of Philadelphia,
University of Pennsyvania, USA). For the transfection
procedure, cells were grown to 60 % confluence, and
EP4, c-Jun and PDK1 siRNAs,control siRNA,and expres-
sion vector were transfected using the lipofectamine
2000 reagent according to the manufacturer’s instruc-
tions. Briefly, the lipofectamine reagent was incubated
with serum-free medium for 5 min. Subsequently, a mix-
ture of respective siRNA was added. After incubation for
20 min at room temperature, the mixture was diluted
with medium and added to each well. The final concentra-
tion of siRNAs in each well was 100 nmol/L. After cultur-
ing for 30 h, cells were washed and resuspended in new
culture medium in the presence or absence of dmPGE2
for Western blot and cell growth and gel mobility shift
assays.
Transient transfection assay
The human PDK1 promoter ligated to the luciferase
reporter gene were a gift from Drs. Michalik and Des-
vergne (Center for Integrative Genomics, University of
Lausanne, Lausanne, Switzerland) and have been reported
previously [17]. The PDK1 promoter construct contains ∼
663 bp of the human PDK1 promoter connected to the
pGL2 vector. Briefly, normal bronchial epithelial cells were
seeded at a density of 5 × 105 per well in 24-well dishes
and grown to 50–60 % confluence. For each well, 0.4 μg
of the above PDK1 plasmid DNA constructs, with or with-
out 0.5 μg of the internal control phRL-TK Synthetic
Renilla Luciferase Reporter Vector, were co-transfected
into the cells using lipofectamine 2000 reagent . After
24 h of incubation, cells were treated with or without
dmPGE2 for 4 h. The preparation of cell extracts and
measurement of luciferase activities were carried out using
the Dual-Luciferase Reporter kit according to recommen-
dations by the manufacturer (Promega). The assays for
firefly luciferase activity and Renilla luciferase activity
were performed sequentially in a Labsystems Luminoskan
Ascent luminometer equipped with dual injectors. Changes
in firefly luciferase activity were calculated and plotted after
normalization with changes in Renilla luciferase activity
within the same sample.
Cell viability assay
Normal bronchial epithelial cells were plated at the indi-
cated densities (2 × 103 cells/well) in 96-well multiwell
culture plates (Costar). Cells were treated with inhibitor
or antagonist for 2 h before exposure of the cells to
PGE2 in the culture medium (containing 10 % FBS). In
separate experiments, cells were transfected with con-
trol, PDK1, EP4 or c-Jun siRNAs or expression vector
for 40 h before exposure to PGE2 for up to 4 days. Cell
proliferation was evaluated using the CellTiter-Glo Lu-
minescent Cell Viability Assay, a homogenous method
of determining number of viable cells in culture based
on quantitation of the ATP present which signals the
presence of metabolically active cells.
Statistical analysis
All experiments were repeated a minimum of three
times. All data from western blot analysis, real-time
PCR, and luciferase assays were expressed as mean ± SD.
In cell viability assay, the bar graphs represented the
mean ± s.d. of relative cell viability compared to the con-
trol group of at least three independent experiments. In
western blot analysis, the optical densities (OD) of
pPDK1, PDK1, EP4 and C-Jun were normalized to the
OD of GAPDH in the same membrane. The data repre-
sented the mean ± s.d. of relative OD compared to the
control group of at least three independent experiments
with three samples in each. In transient transfection
assay, the bar graphs represent the mean ± s.d. of relative
luciferase activities compared to the control group of at
least three independent experiments. One-way anova
analyses followed by the Least Significant Difference
(LSD) test were performed. Asterisks showed in the fig-
ures indicate significant differences of experimental
groups in comparison with the corresponding control
condition. P-values <0.05 were considered statistically
significant.
Results
PGE2 increases cell proliferation and phosphorylation and
expression of PDK1 in HBEc14-KT and BEAS2B cells
PGE2 has been shown to stimulate lung cancer cell prolif-
eration [18]. To examine the effects of PGE2 on human
bronchial epithelial cell proliferation, HBEc 14-KT and
BEAS2B cells were treated with increased concentrations
of dmPGE2 for 72 h. As shown in Fig. 1a, PGE2 stimulates
normal bronchial epitheial cell proliferation in a dose-
dependent manner with maximal effect at a concentration
of 1 μM, compared to the control group (1.604 ± 0.046 vs
1.000 ± 0.046 in BEAS2B, P <0.01; 1.665 ± 0.023 vs 1.000
± 0.017 in HBEc14-KT, P <0.01). Exposure to PGE2 en-
hances the phosphorylation and expression of PDK1 in a
dose-dependent and time-dependent manner with max-
imal effect at a concentration of 1 μM at 2–4 h (Fig. 1b).
pPDK1 and PDK1 reached their peaks at 4 h with the con-
centration of 1 μM of dmPGE2, compared to the control
group (3.414 ± 0.243 vs 1.000 ± 0.135 and 1.512 ± 0.087 vs
1.001 ± 0.129 in BEAS2B, P <0.01, P <0.05; 1.373 ± 0.092
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Fig. 1 (See legend on next page.)
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vs 1.000 ± 0.142 and 1.415 ± 0.726 vs 1.000 ± 0.130 in
HBEc14-KT, P <0.01, P < 0.01). pPDK1 and PDK1 reached
their peaks with the concentration of 1 μM of dmPGE2
after incubation for 4 h, compared to the control group
(2.812 ± 0.317 vs 1.000 ± 0.216 and 5.214 ± 0.478 vs
1.000 ± 0.198 in BEAS2B, P <0.01, P <0.01; 2.754 ±
0.139 vs 1.000 ± 0.141 and 2.351 ± 0.286 vs 1.000 ±
0.127 in HBEc14-KT, P <0.01, P <0.01). To evaluate
the role of PDK1 in PGE2-induced cell proliferation,
PDK1 was silenced with siRNA or pre-treated with
PDK1 inhibitor OSU-03012 (2 μM) in the cell lines
(Fig. 1c and d). PDK1 inhibitor (OSU-03012) decreased
cell proliferation induced by treatment with PGE2
(1.279 ± 0.030 vs 1.463 ± 0.005 in BEAS2B, P <0.01;
1.211 ± 0.142 vs 1.918 ± 0.038 in HBEc14-KT, P <0.01).
PDK1 siRNA decreased cell proliferation induced by
treatment with PGE2 (1.177 ± 0.038 vs 1.708 ± 0.127 in
BEAS2B, P <0.05; 1.272 ± 0.052 vs 2.428 ± 0.073 in
HBEc14-KT, P <0.01). In contrast, transfection of cells
with PDK1 plasmid increases cell proliferation induced by
PGE2 (1.653 ± 0.042 vs 1.381 ± 0.067 in BEAS2B, P <0.05;
1.681 ± 0.033 vs 1.395 ± 0.057 in HBEc14-KT, P <0.01)
(Fig. 1e).
Having established a role for PDK1 in PGE2-stimulated
normal bronchial epithelial cell proliferation, we exam-
ined whether the effects of PGE2 on PDK1 expression
occur at the transcriptional level. We found that PGE2
induces the expression of PDK1 mRNA (3.462 ± 0.103
vs 1.000 ± 0.020 in BEAS2B, P <0.01; 6.218 ± 0.138 vs
1.008 ± 0.069 in HBEc14-KT, P <0.01) (Fig. 1f ) and
activity of PDK1 gene promoter (1.666 ± 0.177 vs 1.000 ±
0.039 in BEAS2B, P <0.05; 2.714 ± 0.187 vs 1.000 ± 0.043
in HBEc14-KT, P <0.01) (Fig. 1g). We therefore conclude
that PGE2 increases cell proliferation in normal bronchial
epithelial cells by activation of the PDK1.
EP4 mediates the cell proliferation and increased
expression and activation of PDK1 induced by PGE2 in
HBEc14-KT and BEAS2B cells
PGE2 binds to and activates four distinct receptor sub-
types named EP1-4. EP4 has been shown to a target
molecule in cancer cell proliferation [19]. To investigate
the mechanisms involved in PGE2-mediated bronchial
epithelial cell proliferation, we transfected cells with EP4
siRNA or pre-treated cells with the EP4 antagonist
AH23848 (10 μM). After pre-treatment with EP4 siRNA or
antagonist, cell proliferations induced by PGE2 decreased
(Fig. 2a and b). EP4 antagonist AH23848 decreased cell
proliferation induced by PGE2 (1.456 ± 0.046 vs 2.078 ±
0.299 in BEAS2B, P <0.01; 1.131 ± 0.052 vs 1.838 ± 0.074 in
HBEc14-KT, P <0.01). EP4 siRNA decreased cell prolifera-
tion induced by treatment with PGE2 (1.243 ± 0.018 vs
1.480 ± 0.029 in BEAS2B, P <0.05; 1.086 ± 0.124 vs 1.866 ±
0.015 in HBEc14-KT, P <0.01). This effect was associ-
ated with inhibition of phosphorylation and expression
of PDK1 (Fig. 2c and d). EP4 antagonist AH23848 de-
creased the phosphorylation (1.213 ± 0.013 vs 1.457 ±
0.021 in BEAS2B, P <0.05; 1.198 ± 0.019 vs 1.562 ± 0.029
in HBEc14-KT, P <0.05) and expression of PDK1 (1.012 ±
0.008 vs 1.452 ± 0.025 in BEAS2B, P <0.05; 1.213 ± 0.019
vs 1.483 ± 0.024 in HBEc14-KT, P <0.05) induced by
dmPGE2. EP4 siRNA decreased the phosphorylation
(0.987 ± 0.019 vs 1.621 ± 0.038 in BEAS2B, P <0.05;
1.242 ± 0.022 vs 1.765 ± 0.031 in HBEc14-KT, P <0.05)
and expression of PDK1 (1.056 ± 0.011 vs 1.513 ± 0.018
in BEAS2B, P <0.05; 1.356 ± 0.028 vs 2.107 ± 0.039 in
HBEc14-KT, P <0.05) induced by dmPGE2. It also de-
creased PDK1 gene promoter activity (1.104 ± 0.113 vs
1.716 ± 0.088 in BEAS2B, P <0.05; 1.187 ± 0.111 vs
1.468 ± 0.101 in HBEc14-KT, P <0.01) induced by dmPGE2
(Fig. 2e). So we conclude that EP4 mediates cell pro-
liferation induced by PGE2 in normal bronchial epi-
thelial cells.
The role of transcription factor c-Jun in PGE2 induction of
PDK1 and cell growth
The PDK1 gene promoter contains multiple transcrip-
tion factor-binding sites, including two sites for c-Jun.
Then we explored the role of c-Jun in mediating PGE2-
induced PDK1 expression in normal bronchial epithelial
cells. PGE2 induces the expression of c-Jun protein in a
time-dependent and dose-dependent manner (Fig. 3a).
C-Jun reached its peaks at 2 h in BEAS2B cells and 4 h
in HBEc14-KT cells with the concentration of 1 μM of
dmPGE2, compared to the control group (2.561 ± 0.189
vs 1.000 ± 0.063 in BEAS2B, P <0.01; 1.347 ± 0.132 in
HBEc14-KT, P <0.01). c-Jun reached its peak with the
concentration of 1 μM of dmPGE2 after incubation for
4 h, compared to the control group (1.499 ± 0.108 vs
1.001 ± 0.063 in BEAS2B, P <0.01; 1.536 ± 0.174 vs 1.000 ±
0.024 in HBEc14-KT, P <0.01). Silencing of c-Jun with
its siRNA decreases cell proliferation (1.115 ± 0.054 vs
1.386 ± 0.072 in BEAS2B, P <0.05; 1.030 ± 0.104 vs
1.495 ± 0.072 in HBEc14-KT, P <0.01) (Fig. 3b) and
(See figure on previous page.)
Fig. 1 The effect of dmPGE2 on human bronchial epithelial cell proliferation and induction of expression and activation of PDK1. a Effects on cell
proliferation. b dmPGE2 increases the phosphorylation and expression of PDK1 in a time- and dose-dependent manner in BEAS2B and HBEc14-KT
cells. c PDK1 inhibitor OSU-03012 decreases cell proliferation induced by dmPGE2 in normal bronchial epithelial cells. d PDK1 siRNA decreases the
cell proliferation induced by dmPGE2 in normal bronchial epithelial cells. e PDK1 plasmid increases the cell proliferation induced by dmPGE2 in
normal bronchial epithelial cells. f Effect on mRNA expression. g Effect on PDK1 promoter activity
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the expression of PDK1 induced by PGE2 (1.105 ±
0.011 vs 2.534 ± 0.029 in BEAS2B, P <0.01; 1.157 ±
0.021 vs 1.892 ± 0.027 in HBEc14-KT, P <0.01) in-
duced by dmPGE2 (Fig. 3d). Transfection with c-Jun
plasmid increases the cell proliferation (1.741 ± 0.051
vs 1.518 ± 0.059 in BEAS2B, P <0.05; 1.772 ± 0.258 vs
1.521 ± 0.027 in HBEc14-KT, P <0.05) (Fig. 3c) and
the expression of PDK1 induced by PGE2 (2.278 ± 0.134
vs 1.196 ± 0.095 in BEAS2B, P <0.05; 2.453 ± 0.141 vs
2.056 ± 0.163 in HBEc14-KT, P <0.05) (Fig. 3e).
Having shown the important role of PDK1 in PGE2-
related NSCLC proliferation, we further investigated
whether the PGE2-mediated up-regulation of PDK1
reflected transactivation of the gene. To this end, we
performed transient transcription experiments using
human PDK1 promoter-reporter constructs connected
to a luciferase reporter gene and found that PGE2 in-
creased PDK1 promoter activity. The induction of
PDK1 promoter activity by PGE2 was inhibited by c-
Jun siRNA (1.319 ± 0.028 vs 1.716 ± 0.069 in BEAS2B,
P <0.01; 1.171 ± 0.071 vs 1.468 ± 0.101 in HBEc14-KT,
P <0.05) (Fig. 3f ). Exogenous overexpression of c-Jun
enhanced the PDK1 promoter activity (1.753 ± 0.037
vs 1.401 ± 0.075 in BEAS2B, P <0.05; 1.762 ± 0.117 vs
Fig. 2 EP4 Mediates the Cell Proliferation and increased expression and activation of PDK1 induced by PGE2 in HBEc14-KT and BEAS2B cells.
a EP4 antagonist AH23848 decreased the cell proliferation induced by dmPGE2 in normal bronchial epithelial cells. b EP4 siRNA decreases the cell
proliferation induced by dmPGE2 in normal bronchial epithelial cells. c EP4 antagonist AH23848 decreased the phosphorylation and expression of
PDK1 induced by dmPGE2 in BEAS2B and HBEc14-KT cells. d EP4 siRNA decreased the phosphorylation and expression of PDK1 induced by
dmPGE2 in BEAS2B and HBEc14-KT cells. e Effect on PDK1 promoter activity
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1.468 ± 0.101 in HBEc14-KT, P <0.01) (Fig. 3g). The
induction of PDK1 gene promoter activity by PGE2
was abrogated when the one of c-Jun sites at -4382 bp was
mutated in the PDK1 gene promoter, suggesting a critical
role for c-Jun in mediating the effect of PGE2 on
PDK1 gene promoter activity (Fig. 3h). dmPGE2 in-
creased PDK1 promoter activity (2.432 ± 0.358 vs 1.000 ±
0.039 in BEAS2B, P <0.05); point mutation of c-Jun with
ac to tt at −4028 site could not derease PDK1 promoter
activity (1.9832 ± 0. vs 1.000 ± 0.024 in BEAS2B, P <0.05);
point mutation of c-Jun site with ac to tt at -4382 bp
dereased PDK1 promoter activity (1.010 ± 0.011 vs
1.000 ± 0.039 in BEAS2B, P <0.05);
Discussion
The transformation is driven by both endogenous and
exogenous factors including chemical agents that induce
the activation of cancer-promoting genes. Accumulating
epidemiologic and clinical data provide a strong link
between inflammation and cancer initiation and progres-
sion [20, 21], but the molecular inflammatory determi-
nants remain to be established. COX-2 derived PGE2 is
a proinflammatory bioactive lipid and is the major pros-
taglandin produced in many human solid tumors, in-
cluding cancer of the colon [22], stomach [23], breast
[24] and lung [25]. PGE2 and its receptors play an essen-
tial role in promoting cancer progression. For example,
PGE2 significantly enhanced carcinogen induced colon
tumor incidence and multiplicity in rats. PGE2 acceler-
ates intestinal adenoma growth in ApcMin mice [26].
However, the effects of PGE2 on human bronchial epi-
thelial cells are not clear.. Therefore, we will focus on
PGE2 and its receptors and its downstream targets in
human bronchial epithelial cells, and explore the po-
tential mechanism. This is the first study on the ef-
fects of PGE2 in inducing the activation of cancer-
promoting genes in normal bronchial epithelial cells.
In concordance with studies performed in tumor cells
before, we demonstrate PGE2 increases normal bronchial
epithelial cell proliferation, through increased PDK1 gene
expression that is dependent on EP4 and induction
of c-Jun. It unveils a novel role of c-Jun and PDK1
in mediating epithelial cell hyperplasia induced by
PGE2.
Fig. 3 c-Jun Mediates the Cell Proliferation and increased expression and activation of PDK1 induced by PGE2 in HBEc14-KT and BEAS2B cells.
a dmPGE2 increases expression of c-Jun in a time- and dose-dependent manner in BEAS2B and HBEc14-KT cells. b c-Jun siRNA decreases the cell
proliferation induced by dmPGE2 in normal bronchial epithelial cells. c c-Jun plasmid increases the cell proliferation induced by dmPGE2 in normal
bronchial epithelial cells. d c-Jun siRNA decreases expression of PDK1 induced by dmPGE2 in BEAS2B and HBEc14-KT cells. e c-Jun plasmid
increases expression of PDK1 induced by dmPGE2 in BEAS2B and HBEc14-KT cells. f Effect of c-Jun siRNA on PDK1 promoter activity. g Effect of
c-Jun plasmid on PDK1 promoter activity. h Effects of c-Jun point-moutations on PDK1 promoter activity
Fan et al. Respiratory Research  (2015) 16:149 Page 7 of 10
Three-phosphoinositide-dependent protein kinase-1
(PDK1) is a major mediator of cellular signaling between
phosphoinositide-3 kinase and various intracellular serine/
threonine kinases, including PKB, p70 ribosomal S6 kin-
ase, serum and glucocorticoid-inducible kinase, and pro-
tein kinase. PDK1 is able to phosphorylate Thr-308 on
PKBα [27, 28], which has been shown to play a crucial role
in normal and pathophysical conditions. Activation of
PDK1 has been shown to regulate cell survival and
growth, cell cycle progression, gene expression and differ-
ention [9, 29]. Autophosphorylation and growth-factor-
induced phosphorylation in its activation loop is required
for PDK1 activity [30]. S241A mutation abolished PDK1
catalytic activity completely, which suggests phosphoryl-
ation at Ser-241 is important for PDK1 signaling [31].
There is increasing evidence that PDK1 is involved in can-
cer progression and invasion. Tissue microarray analysis
of human invasive breast cancer has revealed that phos-
phorylation of PDK1 on Ser-241 was strongly enhanced in
90 % of the samples tested [11]. Immunohistochemical
analysis using anti-phospho-Tyr-9 antibodies demon-
strated that the level of Tyr-9 phosphorylation is increased
markly in diseased lung, liver, colon, and breast tissue
compared to normal tissue [12]. Studies have shown that
angiotension-II-induced focal adhesion formation is inhib-
ited by infection with Adeno-PDK1-Y9F via paxillin [10].
This regulation of focal adhesion suggests that PDK1 par-
ticipates in integrating signals that control cell growth,
apoptosis and migration. PDK1 gene has been assoiated
with poor differentiation of late stage lung cancer [32].
PDK1 was shown capable of augmenting tumorigenesis in
tissues harboring ERBB2 amplifications [33], PTEN de-
letions [34], and mutations in the catalytic subunit of
phosphoinositide 3-kinase (PIK3CA) [35]. Inhibition of
PDK1 is therefore expected to attenuate tumors associated
with deregulated PIK3CA/PTEN signaling. Indeed, hypo-
morphic mutation of PDK1 in Pten +/− mice delays the
onset of tumorigenesis, and small molecule inhibitors of
PDK1 inhibit tumor xenografts and lung colonization
[36]. Further, PDK1 inactivation effectively attenuated the
development of Kras oncogene-driven pancreatic cancer,
but not NSCLC, further supporting the importance of
PDK1 in tumor development, albeit, in select cancer types
[37]. Here, we found that PGE2 increased the expression
of PDK1 in bronchial epithelial cells. Overexpression of
PDK1 enhanced cell proliferation, while cells stimulated
with PDK1 inhibitor or siRNA reduced cell growth. These
findings provides the first genetic evidence that PDK1
may also play an essential role in abnormally enhanced
cell proliferation induced by PGE2 in bronchial epithelial
cells, which was convinced in tumor cells in previous
studies. Consistent with former studies, PDK1 inactivations
by small molecule inhibitor of PDK1 or siRNA effectively
attenuated cell proliferation in bronchial epithelial cells,
supporting the potential importance of PDK1 in NSCLC
development. PDK1 also plays a crucial role in metastasis.
This kinase mediates mammary epithelial cell growth and
invasion in the transformed phenotype, in part, by mem-
brane type 1 matrix metalloproteinase (MMP) induction,
which in turn activates MMP-2 and modulates the extra-
cellular matrix proteins decorin and collagen [11]. Knock-
down of PDK1 inhibits spontaneous migration and
epidermal-growth-factor-induced chemotaxis in breast
cancer cells. In severe combined immunodeficiency mice,
PDK1-depleted human breast cancer cells form tumors
more slowly and are defective in extravasation to the lungs
after intravenous injection [38]. These results indicate that
PDK1 plays an important role in regulating malignancy in
breast cancer cells. Moreover, reducing PDK1 expression
in PTEN +/− mice protects these animals from developing
a wide range of tumors [36], thereby providing genetic evi-
dence that PDK1 is a key effector in mediating neoplasia
that result from loss of PTEN. In addition, PDK1 is an
upstream kinase of AKT, which regulates activities of AKT,
in turn, mediates the regulation of tumor cell growth, me-
tastasis, and angiogenesis [39]. All these results validate
PDK1 is a promising anticancer target for the prevention
of tumors.
PGE2 exerts its cellular effects by binding to its cog-
nate receptors (EP1-4) that belong to the family of seven
transmembrane G protein coupled rhodopsin-type re-
ceptors [40]. The central role of PGE2 in tumor-genesis
has been further confirmed through homozygous dele-
tion of its receptors. Mice with homozygous deletion in
EP1 and EP4 receptors, but not EP3, were partially re-
sistant to colon carcinogen mediated induction of aber-
rant crypt foci [41, 42]. EP2 disruption decreases the
number and size of intestinal polyps in APC△716 knock-
out mice [43]. In addition to colorectal cancer, it has
been shown that EP1, 2, and 4 receptors were elevated
whereas EP3 receptor levels were decreased in mam-
mary tumors in COX-2-MMTV mice [44]. It was
showed that PGE2 promotes lung cancer cell migration
via EP4-betaArrestin1-c-Src pathway [45]. In this study,
blockade of EP4 by antagonists or by EP4 siRNA re-
sulted in reduced PDK1 protein expression and activity
of PDK1 promoter, suggesting that EP4 mediates the ef-
fect of PGE2 on PDK1 expression in normal bronchial
epithelial cells. The EP4 receptor can activate several
pathways that involve cell proliferation, adhesion, in-
vasion and migration. These main molecules include
G protein, adenylyl cyclase, protein kinase A, exchange
protein directly activated by cAMP, phosphodiesterase,
phosphatidylinositol 3-Kinase, extracellular signal-regulated
kinase. Most recently, we found that the EP4 receptor could
increase the expression of JNK [16], which has been found
to play a pivotal role in activating transcription factors
(including c-Jun) that increase cellular growth and
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tumor formation in NSCLC cells. We also showed
that activation of PI3-K, PKA, and JNK induced by
EP4 was involved in the effect of PGE2 on c-jun in
NSCLC [46].
Specific mitogen-activated protein kinase (MAPK) cas-
cades control the activation of fos and jun family proto-
oncogenes and their protein products (c-Jun and c-Fos)
are known as the AP-1 family members. These “early re-
sponse protooncogene” products dimerize to form the
AP-1 transcription factor, a converging point that regu-
lates the expression of genes involved in cell proliferation,
differentiation, transformation, inflammation, pulmonary
defense, and autoregulation of AP-1 gene transcription
[46]. Early studies [47, 48] suggested that c-Jun had a role
in early events in the pathogenesis of lung cancers because
it was highly expressed in 31–50 % of patients with non-
small cell cancers, and it was also upregulated in atypical
bronchial epithelium. One study showed a transgenic
mouse model directing conditional expression of the
dominant-negative c-Jun mutant TAM67 in lung epithe-
lial cells decreased tumor number and overall lung tumor
burden in chemically induced mouse lung tumor models
[49]. c-Jun is an important transcriptional activator of
PDK1. Notably, expression of PDK1 is sufficient to restore
tumor growth after c-Jun knockdown in melanoma cells,
suggesting that PDK1 is an important mediator of c-Jun
oncogenic activities [50]. Consistent with this, we found
that PGE2 increased the expression of c-Jun and exogen-
ous overexpression of c-Jun enhanced bronchial epithelial
cells proliferation and expression of PDK1, whereas inhib-
ition by PDK1 inhibitor or siRNA caused inhibitions of
cell growth and expression of PDK1. This suggests that c-
Jun is an upstream regulator of PDK1 signaling. Induction
of c-Jun by PGE2 regulates the expression and activation
of PDK1 and cell growth. It indicated c-Jun might play an
important role in the potential mechanism of abnormal
cell proliferation in brochial epithelial cells.
Conclusion
In summary, our findings demonstrate that PGE2 stimu-
lates human bronchial epithelial cell proliferation
through activations of EP4-related signal and c-Jun,
which, in turn, increases activation and expression of
PDK1. This suggests that PDK1 and c-Jun might play an
important role in human bronchial epithelial cells
thereby influencing their growth.
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